RGEN Stock Overview
Develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Repligen Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$138.90 |
| 52 Week High | US$211.13 |
| 52 Week Low | US$113.50 |
| Beta | 0.96 |
| 11 Month Change | -6.91% |
| 3 Month Change | -6.20% |
| 1 Year Change | -13.30% |
| 33 Year Change | -48.90% |
| 5 Year Change | 54.52% |
| Change since IPO | 1,255.12% |
Recent News & Updates
Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects
Nov 12Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet
Nov 08
Is It Time To Consider Buying Repligen Corporation (NASDAQ:RGEN)?
Oct 14Recent updates
Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects
Nov 12Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet
Nov 08Is It Time To Consider Buying Repligen Corporation (NASDAQ:RGEN)?
Oct 14Repligen Corporation's (NASDAQ:RGEN) Intrinsic Value Is Potentially 28% Above Its Share Price
Sep 08Repligen Corporation (NASDAQ:RGEN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Jul 31We Think Repligen (NASDAQ:RGEN) Can Stay On Top Of Its Debt
Jul 15Repligen: Strong Filtration Growth, Offset By Other Challenges
Jul 13Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge
Jun 14Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?
Jun 10Repligen Stock: Still Quite Overvalued
May 30Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models
May 03Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Apr 30Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet
Apr 15At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?
Feb 13Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Jan 08Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price
Dec 19What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?
Nov 01Is Repligen (NASDAQ:RGEN) Using Too Much Debt?
Oct 17Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?
Sep 29Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade
Aug 09Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?
Jul 17Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?
Jul 03With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case
Jun 19Shareholder Returns
| RGEN | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -7.7% | -5.8% | -1.0% |
| 1Y | -13.3% | 1.7% | 30.3% |
Return vs Industry: RGEN underperformed the US Life Sciences industry which returned 1.2% over the past year.
Return vs Market: RGEN underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| RGEN volatility | |
|---|---|
| RGEN Average Weekly Movement | 7.1% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RGEN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RGEN's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 1,783 | Olivier Loeillot | www.repligen.com |
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes.
Repligen Corporation Fundamentals Summary
| RGEN fundamental statistics | |
|---|---|
| Market cap | US$7.20b |
| Earnings (TTM) | -US$8.09m |
| Revenue (TTM) | US$633.51m |
12.3x
P/S Ratio-961.3x
P/E RatioIs RGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGEN income statement (TTM) | |
|---|---|
| Revenue | US$633.51m |
| Cost of Revenue | US$308.99m |
| Gross Profit | US$324.52m |
| Other Expenses | US$332.62m |
| Earnings | -US$8.09m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 51.23% |
| Net Profit Margin | -1.28% |
| Debt/Equity Ratio | 25.9% |
How did RGEN perform over the long term?
See historical performance and comparison